Timeline

Voting rights breakdown

Gemeldete wirtschaftlich Berechtigte · 4

Eine einzelne, gemeinsam eingereichte Meldung: Der Stimmrechtsanteil gilt für die gesamte Gruppe, nicht für jede Person.

• Omega Fund IV LP Cayman Islands36.57%
• Otello Stampacchia36.57%
• Richard Lim36.57%
• Anne-Mari Paster36.57%

Notice details

Beneficial owner

Omega Fund IV LP Cayman Islands

Each investor has undertaken severally, not jointly, to exchange its shares in Kuros against shares in Cytos as outlined in the combination agreement between Cytos and Kuros dated December 1, 2015, and subject to the terms and conditions set forth therein. At the closing of the transaction, Cytos is expected to issue between 353,006,886 new registered shares (assuming 90% of Kuros shares are exchanged for new Cytos shares) and 392,229,873 new registered shares (assuming 100% of Kuros shares are exchanged for new Cytos shares). Accordingly, the number of shares/voting rights pursuant to the entry in the commercial register will be between 461,022,162 and 500,245,149 at the time the investors will actually become shareholders in Cytos. It is expected that the investors will hold between 7.90% and 8.57% total equity securities and purchase positions post closing. Omega Fund IV GP, LP (Cayman Islands) is the general partner of Omega Fund IV LP, a multi-investor fund. Omega Fund IV GP Manager, Ltd.(Cayman Islands), is the general partner of Omega Fund IV GP, LP. Messrs. Stampacchia, Lim and Ms. Paster are members, and Omega Fund Management LLC is the management company of Omega Fund IV GP Manager, Ltd. Clessidra LLC is the sole member of Omega Fund Management LLC. Mr. Stampacchia is the sole member of Clessidra LLC. All of the named companies have their principal address c/o Omega Fund Management LLC, 185 Dartmouth Street, Suite 502, Boston, MA 02116, USA.